Advertisement
Ear/Nose/Throat
Subscribe to Ear/Nose/Throat
View Sample

FREE Email Newsletter

<i>Patent Watch: </i>Gene patents flow into New England

March 29, 2011 8:34 pm | by Mass High Tech: The Journal of New England Technology | News | Comments

Suffolk Law School professor Kirk Teska: Gene patents are back in the news, so let's take a look at several gene related patents and published patent applications naming New England inventors of the last year.

FDA Approves New Treatment for a Type of Late-Stage Skin Cancer

March 25, 2011 9:36 am | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., March 25, 2011 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved Yervoy (ipilimumab) to treat patients with late-stage (metastatic) melanoma, the most dangerous type of skin cancer. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO...

Gateway to Hope: Missouri Nonprofit Leads the Fight against Breast Cancer by Providing Donated Medical and Surgical Care at No Cost to Patients

March 24, 2011 4:34 am | by Bio-Medicine.Org | News | Comments

ST. LOUIS, March 24, 2011 /- Frustrated at seeing patients die because of lack of insurance or financial means, Dr. David A. Caplin and Dr. Marlys E. Schuh founded Gateway to Hope in St. Louis, Missouri in 2005. Based on the belief that every person diagnosed with breast cancer should be...

Advertisement

Student's love for family apparent in his 2 for OneShot system

March 22, 2011 10:35 am | by Arizona State University | News | Comments

From homelessness to greatness, ASU student Tyler Eltringham has seen the ups and downs of life. read more

Life Technologies Initiates Clinical Trials Leading to 510(k) Submission of a Class I and Class II HLA Sequence-Based Typing Solution

March 21, 2011 4:35 am | by Bio-Medicine.Org | News | Comments

CARLSBAD, Calif., March 21, 2011 /- Life Technologies Corporation (Nasdaq: LIFE ) today announced that it is the first life science tools provider entering clinical trials to prove the safety and effectiveness of their DNA sequence-based typing (SBT) platform for analysis of the Human...

Research: Prostate cancer patients opt for more expensive treatment

March 17, 2011 11:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Men diagnosed with prostate cancer have been rapidly adopting new, more expensive treatment options, even without proof of their cost-effectiveness, according to research by the Dana-Farber/Brigham and Women's Hospital Cancer Center.

Research: Prostrate cancer patients opt for more expensive treatment

March 17, 2011 9:32 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Men diagnosed with prostate cancer have been rapidly adopting new, more expensive treatment options, even without proof of their cost-effectiveness, according to research by the Dana-Farber/Brigham and Women's Hospital Cancer Center.

Statin drugs may lessen prostate cancer chances

March 14, 2011 11:37 am | by Mass High Tech: The Journal of New England Technology | News | Comments

A study conducted by researchers from Brigham and Women's Hospital in Boston shows that taking cholesterol-lowering drugs in the statin family is linked to reduced diagnoses of prostate cancer.

Advertisement

Researchers Present Key Findings Comparing PEM to MRI for Identification of Contralateral Breast Cancer at the National Consortium of Breast Centers (NCBC) Conference

March 14, 2011 6:34 am | by Bio-Medicine.Org | News | Comments

LAS VEGAS, March 14, 2011 /- Researchers presented data demonstrating increased specificity of Positron Emission Mammography (PEM) when compared to  MRI for the detection of breast cancer at the National Consortium of Breast Centers' 21st Annual National Interdisciplinary Breast...

Ferring Pharmaceuticals, Inc. Congratulates R & B and Pop Icon Gloria Gaynor, Named 'Woman of the Year' by Arthritis Foundation

March 11, 2011 11:36 am | by Bio-Medicine.Org | News | Comments

PARSIPPANY, N.J., March 11, 2011 /- Ferring Pharmaceuticals Inc. congratulates GRAMMY® award-winning recording artist Gloria Gaynor, who will receive the inaugural Woman of the Year award from the Arthritis Foundation's New York Chapter.  As part of the Foundation's arthritis...

International Prostate Cancer Treatment Expert Dr. David B. Samadi Supports Kenyan Minister of Medical Services, Peter Anyang Nyong'o's Decision to Travel to the U.S. for Pros...

March 10, 2011 9:36 am | by Bio-Medicine.Org | News | Comments

NEW YORK, March 10, 2011 /- Last Saturday, Kenyan Minister of Medical Services Peter Anyang Nyong'o stepped off a plane and onto Kenyan soil to a hero's welcome.  His return marked the end of a nearly year long struggle with prostate cancer.  Having been met with the harsh...

OXIS International to Hold Business Update Conference Call on March 22

March 10, 2011 4:36 am | by Bio-Medicine.Org | News | Comments

BEVERLY HILLS, Calif., March 10, 2011 /- OXIS International, Inc., (OTC Bulletin Board: OXIS ;  Paris: OXI) today announced that it will hold a conference call with investors on Tuesday, March 22, 2011 at 11:00 a.m. Eastern (8:00 a.m. Pacific). During the call Anthony Cataldo, Chief...

Sam's Club® Offers Free Allergy Health Screenings

March 10, 2011 2:34 am | by Bio-Medicine.Org | News | Comments

BENTONVILLE, Ark., March 10, 2011 /- Warm weather will soon be on its way, bringing joy to many people looking forward to the sunshine and blossoming flowers.  However, the changing of seasons also marks the onset of spring allergies for more than 40 million Americans.  On...

Advertisement

Genus Oncology, LLC Announces Orphan Drug Status for GO-203-2c for Treatment of Pancreatic Cancer

March 8, 2011 3:33 am | by Bio-Medicine.Org | News | Comments

VERNON HILLS, Ill., March 8, 2011 /- Genus Oncology, LLC, a clinical-stage company focused on commercializing novel drugs for treatment of cancer, announced it has received an Orphan Drug Designation from the FDA's Office of Orphan Products Development for its Mucin 1 (MUC1) targeting...

IRIDEX to Present at the Roth OC Growth Stock Conference in Dana Point, CA

March 7, 2011 9:35 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., March 7, 2011 /- IRIDEX Corporation (Nasdaq: IRIX ) today announced that management is scheduled to make an investor presentation at the ROTH 23rd Annual OC Growth Stock Conference on Monday, March 14, at 2:30 pm Pacific Time.  The conference is being held...

FDA: Risk of Oral Birth Defects in Children Born to Mothers Taking Topiramate

March 4, 2011 6:33 am | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., March 4, 2011 /PRNewswire-USNewswire/ -- New data suggest that the drug Topamax (topiramate) and its generic versions increase the risk for the birth defects cleft lip and cleft palate in babies born to women who use the medication during pregnancy, the U.S. Food and...

FCC Approval of Finite Element Method for Biomedical Transmitters Puts ANSYS Software in the Spotlight

March 3, 2011 4:37 am | by Bio-Medicine.Org | News | Comments

PITTSBURGH, March 3, 2011 /- For specific electromagnetic applications in the healthcare industry, HFSS™ software from ANSYS (Nasdaq: ANSS ) can now provide proof that a biomedical device transmitter design meets Federal Communications Commission (FCC) standards -- a ruling that...

Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government

March 2, 2011 6:36 am | by Bio-Medicine.Org | News | Comments

EAST SETAUKET, N.Y., March 2, 2011 /- Lixte Biotechnology Holdings (OTC: LIXT) announced today that the company has received a $244,479.25 grant under the Qualifying Therapeutic Discovery Project (QTDP).  This grant was awarded to further development and commercialization of Lixte's...

Naviscan Announces European Launch of Positron Emission Mammography

March 2, 2011 4:35 am | by Bio-Medicine.Org | News | Comments

VIENNA, March 2, 2011 /- Naviscan, Inc., announces the European launch of the Naviscan Positron Emission Mammography (PEM) scanner at two prestigious radiology conferences in Vienna.  On March 3rd, at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting, a podium...

Omni Bio Pharmaceutical Intends to Expand Type 1 Diabetes Trial to 50 Patients

February 28, 2011 3:35 am | by Bio-Medicine.Org | News | Comments

DENVER, Feb. 28, 2011 /- (OTC Bulletin Board: OMBP ) Omni Bio Pharmaceutical, Inc. ("Omni Bio"), an emerging biopharmaceutical company formed to acquire, license, and develop existing therapies for indications with substantial commercialization potential, has committed to expand its Phase...

FDA Grants Full Approval for PROMACTA® (eltrombopag) for Treatment of Rare Blood Disorder

February 25, 2011 10:36 pm | by Bio-Medicine.Org | News | Comments

PHILADELPHIA, Feb. 25, 2011 /- GlaxoSmithKline (NYSE: GSK ) today announced that the United States Food and Drug Administration (FDA) granted full approval for PROMACTA® (eltrombopag), an oral tablet that can raise platelet counts in patients with the rare blood disorder chronic...

Social Networking's Newest Friend: Genomics

February 23, 2011 7:33 pm | by Massachusetts Institute of Technology | News | Comments

The first large-scale study to combine genome sequencing and social-network analysis solves a mysterious TB outbreak.

Using Amphetamines May Increase Risk of Parkinson's Disease

February 22, 2011 7:35 am | by Bio-Medicine.Org | News | Comments

ST. PAUL, Minn., Feb. 22, 2011 /PRNewswire-USNewswire/ -- New research shows people who have used amphetamines such as benzedrine and dexedrine appear to be at an increased risk of developing Parkinson's disease, according to a study released today that will be presented at the American...

ASU, Mayo Clinic enhance collaboration with formal commitment

February 14, 2011 7:34 am | by Arizona State University | News | Comments

ASU and Mayo Clinic have signed an agreement to broaden and deepen their collaboration in health care, medical research and education.read more

OXIS International to Present at the Lippert/Heilshorn Life Sciences and Medtech Virtual Conference on February 17

February 14, 2011 4:34 am | by Bio-Medicine.Org | News | Comments

BEVERLY HILLS, Calif., Feb. 14, 2011 /- OXIS International, Inc., (OTC Bulletin Board: OXIS ;  Paris: OXI) today announced that Anthony Cataldo, Chief Executive Officer, and Bernie Landes, President, will present to investors as part of the Lippert/Heilshorn & Associates Life...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading